Chembio Diagnostic Systems

Chembio Diagnostic Systems is a commercial-stage diagnostics company specializing in rapid point-of-care tests for infectious diseases. Its core innovation is the proprietary Dual Path Platform (DPP®) technology, which offers enhanced sensitivity and multiplexing capabilities compared to traditional lateral flow assays. The company has a diversified portfolio targeting HIV, syphilis, tropical diseases, respiratory illnesses (including COVID-19), and veterinary health, and is actively advancing its pipeline with support from grants and strategic designations like FDA Breakthrough Device status. Chembio operates as a subsidiary of the global diagnostics group Biosynex.

Proprietary Dual Path Platform (DPP®) technology, a rapid point-of-care diagnostic platform that uses separate paths for sample and detector reagents. It offers enhanced sensitivity, multiplex capability (up to 8 biomarkers), no hook effect, and compatibility with diverse sample types including blood and oral fluid.

Chembio competes in the crowded point-of-care diagnostics market against major players like Abbott (BinaxNOW), Roche, QuidelOrtho, and BD, as well as numerous specialized companies. Its primary competitive advantage is the technical superiority of its DPP® platform, particularly for multiplexed and complex assays, but it faces challenges in matching the commercial scale and brand recognition of the industry giants.